Petula Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -53.80%
- Ebitda -489.41%
- Net Worth -8.14%
- Total Assets %
About Petula Pharmaceuticals
Petula Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 May 2007 and has a history of 17 years and eight months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Namrata Arora and Prajwal Arora serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74120DL2007PTC163872
-
Company No.
163872
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 May 2007
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Petula Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Namrata Arora
|
Director | 21-Aug-2024 | Current |
|
Prajwal Arora
|
Director | 27-Dec-2022 | Current |
Financial Performance of Petula Pharmaceuticals.
Petula Pharmaceuticals Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 53.8% decrease in profit. The company's net worth dipped by a decrease of 8.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Petula Pharmaceuticals?
In 2018, Petula Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Famberz Biotech Private LimitedNamrata Arora and Prajwal Arora are mutual person
-
Bhagwan Dass Pharmaceutical Limited
Namrata Arora and Prajwal Arora are mutual person
-
Shri Jiwanda Ram Biotech Private Limited
Prajwal Arora is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Petula Pharmaceuticals?
Unlock and access historical data on people associated with Petula Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Petula Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Petula Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
